v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities                
Net loss $ (9,187) $ 1,539 $ (8,288) $ (10,375) $ (7,648) $ (18,663)    
Adjustments to reconcile net loss to net cash used in operating activities                
Depreciation         271 337    
Non-cash lease expense         62 210    
Change in fair value of SEPA, warrant and revenue base redemption liabilities         (6,469) 1,165    
Change in fair value of contingent earnout liability 996   (700)   (6,406) 120    
Paid-in-kind interest         0 584    
Stock-based compensation expense         5,088 3,512    
Allowance for credit losses         74 96    
Loss on disposal of property and equipment         1 117    
Amortization of debt issuance costs         632 492    
Changes in operating assets and liabilities                
Accounts receivable         24 (540)    
Inventory, net         (1,128) 241    
Prepaid expenses and other assets         (622) 777    
Operating lease liabilities         (62) (81)    
Trade payables and accrued liabilities         (426) (186)    
Net cash used in operating activities         (16,609) (11,819)    
Cash flows from investing activities                
Purchases of property and equipment         (223) (661)    
Proceeds from disposal of property and equipment         0 40    
Net cash used in investing activities         (223) (621)    
Cash flows from financing activities                
Proceeds from the issuance of common stock, net of issuance costs         42,625 20,451    
Proceeds from the exercise of stock options for common stock         49 335    
Proceeds from the issuance of common stock through employee stock purchase plan         270 211    
Debt issuance costs         (613) (520) $ (500) $ (2,600)
Proceeds from the issuance of debt         0 10,000    
Payments on finance lease liabilities         (27) (72)    
Short-swing profit settlement         27 0    
Net cash provided by financing activities         42,331 30,405    
Increase in cash, cash equivalents and restricted cash         25,499 17,965    
Cash, cash equivalents and restricted cash, beginning of period   $ 20,789   $ 8,875 20,789 8,875 8,875  
Cash, cash equivalents and restricted cash, end of period $ 46,288   $ 26,840   46,288 26,840 $ 20,789 $ 8,875
Supplemental disclosures of cash flow information                
Cash paid for interest         2,294 1,557    
Cash paid for income taxes         0 16    
Supplemental disclosure of non-cash items                
Right-of-use assets obtained in exchange for new finance lease liabilities         57 0    
Non-cash capital expenditures included in trade payables         20 20    
Fixed assets purchased through exchange of finance lease right-of-use asset         0 85    
Derecognition of finance lease right-of-use asset         0 (85)    
Fair value of warrants issued with OrbiMed debt         $ 0 $ 366